Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Officers; Compensatory Arrangements of Certain Officers.

As of June27, 2018, the Board of Directors of Supernus Pharmaceuticals,Inc. (the “Company”) appointed Dr.Carrolee Barlow, M.D., Ph.D. as a member of the Board of Directors of the Company. Dr.Barlow will receive an annual Board service fee of $50,000 in 2018, which amount shall be prorated for her actual time of service in 2018. In addition, the Board of Directors granted Dr.Barlow options to purchase 10,213 shares of the Company’s common stock under the Company’s Third Amended and Restated 2012 Equity Incentive Plan at a per share exercise price of $58.15, subject to a four year vesting period.

Dr.Barlow has not been appointed to any committees, nor to date has the Board of Directors made any determination to place her on specific committees. There was no arrangement or understanding between Dr.Barlow and any person to which she was selected as a director. Dr.Barlow has not been a party to any transaction with the Company that the Company would be obligated to report to Item 404(a)of Regulation S-K nor has any such transaction been proposed.

Item 8.01 Other Events.

On June27, 2018, the Company issued a press release announcing the appointment of Dr.Carrolee Barlow, M.D., Ph.D. to the Board of Directors of the Company. A copy of this release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit to Item 8.01 hereof:

Exhibit99.1—Press Release Dated June27, 2018.


SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a18-16343_1ex99d1.htm EX-99.1 Exhibit 99.1     Dr. Carrolee Barlow,…
To view the full exhibit click here

About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.